Home » Newsletters » BioWorld Science

BioWorld Science

March 24, 2014

View Archived Issues

Nanoparticle-mediated in vivo delivery of therapeutic siRNAs

Eisai establishes collaboration to identify anti-Wolbachia drugs to treat filariasis

Adocia reports data for combination of long-acting and fast-acting insulin

New monoclonal antibodies for the treatment of botulism disclosed

4SC Discovery collaborates with Heidelberg University Hospital on new malaria drug

Novan reports phase II data for SB-204

World Tuberculosis Day News: Research shows feasibility of diagnosis via biomarkers in sputum

Phase IIb topline results for cariprazine adjunctive treatment in major depressive disorder

Novartis' BCR-ABL kinase inhibitor ABL-001 enters clinical study

Global Health Innovative Technology Fund grants millions for infectious diseases research

Novel ITK inhibitors divulged by Principia Biopharma

Researchers at Amgen disclose novel GKRP/GK interaction inhibitors

Merck KGaA presents novel DDR2 inhibitors

Results from first-in-human study of a direct thrombin inhibitor, CTB-001

Geron reports Myelofibrosis IST trial placed on partial clinical hold

Biotie to regain global rights to tozadenant

Endocyte reports results from phase IIb study of vintafolide in NSCLC

ArevaMed presents phase I data for 212Pb-TCMC-trastuzumab

FDA approves Otezla for psoriatic arthritis

Significant improvements in psoriasis symptoms observed after oral treatment with baricitinib

FDA approves Xolair for chronic idiopathic urticaria

CHMP issues positive opinion for simeprevir in chronic HCV infection

Efient approved in Japan for patients with ischemic heart disease undergoing PCI

Xtandi approved in Japan for castration-resistant prostate cancer

Health Canada approves Alprolix for hemophilia B

Lonsurf approved in Japan for recurrent colorectal cancer

EMA committee recommends approval of Vynfinit and companion imaging agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...